They showed that concomitant inhibition of NRF2 using ML385 and of GPX4 using FIN56 or RSL3 synergistically eradicate AML through ferroptosis and apoptosis induction, suggesting that such a combination of therapy may represent a promising approach for the treatment of AML. The gene discussed is NFE2L2; the disease is acute myeloid leukemia.